ERBB2 and breast cancer: No statistically significant difference in QALY was observed between adjuvant and neoadjuvant treatment groups (<i>p</i> = 0.296).<h4>Conclusion</h4>Overall, while adjuvant Trastuzumab remains the most cost-effective strategy for patients with <i>HER2+</i> breast cancer, adopting a neoadjuvant Trastuzumab approach does not appear to pose a significant economic disadvantage.